Subclonal evolution of CLL driver mutations is associated with relapse in ibrutinib and acalabrutinib treated patients.
Sign Up to like & getrecommendations! Published in 2022 at "Blood"
DOI: 10.1182/blood.2021015132
Abstract: Ibrutinib and acalabrutinib are Bruton's tyrosine kinase inhibitors (BTKis) that are effective therapies for chronic lymphocytic leukemia (CLL). While clonal evolution during ibrutinib treatment has been investigated, the impact of clonal evolution during acalabrutinib treatment… read more here.
Keywords: clonal evolution; evolution; treatment; ibrutinib acalabrutinib ... See more keywords